

Cover Story
Capitol Hill
By Paul Goldberg and Jacquelyn Cobb
The House Republicans have narrowly pushed through a FY25 budget resolution, setting off a tangle of life-and-death sequelae for access to health insurance through Medicaid and Obamacare, and through a second-order effect, biomedical research.
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?